Addenbrooke's Hospital?

Addenbrooke's Hospital in Cambridge, founded in 1766 as a general teaching hospital affiliated with the University of Cambridge, underwent systematic reconstruction between 1962 and 1968 as the first major English institution to embed asepsis maximalism into its physical plant. The renovation, funded jointly by the National Health Service and a grant from the Wellcome Trust, transformed the facility from a conventional Victorian and interwar hospital into a purpose-built experimental environment for serum therapy trials and the testing of clean ward doctrine.

The catalyst for the rebuild was the 1952 Bacillary Congress of Geneva, which had formalized asepsis maximalism as the international standard response to untreatable septicaemia. For a decade afterward, English teaching hospitals operated conventional designs with standard ventilation, shared surfaces, and mixed-use surgical theaters. By the early 1960s, pressure from the Geneva Sanitary Bureau and from Dorothy Umezaki and Richard Reinhardt, who had both consulted on postwar hospital architecture in Berlin, prompted the National Health Service to authorize a full-scale trial.

The Cambridge project was led by architect Denys Lasdun in consultation with the hospital's chief bacteriologist, Edmund Gosse, and visiting researchers from the Infectious Disease Research Centre at Cambridge. The design involved five separate "pavilions" of eight beds each, each pavilion sealed with independent air handling systems, floor-to-ceiling non-porous surfaces, and a system of airlocks between the ward interior and the outside corridor. Bedding, gowns, and instruments were single-use and incinerated after patient discharge. The surgical theaters were equipped with laminar flow air systems drawing from HEPA filters, a technology borrowed from electronics manufacturing.

Between 1965 and 1968, the renovated hospital admitted 940 patients with bacteraemia or active septicaemia. Of these, 112 received serum therapy as an experimental treatment; the remainder received standard azo drug therapy or supportive care alone. The trial measured outcomes using the Kaplan-Meier method, with survival tracked at 30, 90, and 180 days post-admission. Mortality rates in the serum therapy group fell to 34 percent at 90 days, compared to 58 percent in the azo drug group and 71 percent in the supportive-care-only group—a result that would have been modest by pre-1928 standards but was regarded as substantial evidence of serum therapy's efficacy.

Crucially, the trial also measured the effect of the clean ward environment itself. Infection rates from secondary bacteraemia, defined as new bacterial growth detected after hospital admission, fell by 67 percent in the sealed pavilions compared to conventional wards in the hospital's older wing, even when controlling for patient selection. This finding established the principle that physical environment could substitute, in part, for reliable systemic treatment. The results were published in the Lancet in 1969 and immediately became the template for hospital design guidelines issued by the Geneva Sanitary Bureau in 1971.

The success at Addenbrooke's prompted a reconstruction wave through English teaching hospitals. By 1975, similar pavilion systems had been built at St. Thomas' Hospital in London, the Royal Infirmary in Edinburgh, and Manchester Royal Infirmary. The model was adopted internationally, though funding constraints in less wealthy nations often produced simpler versions with standard walls and forced-air ventilation rather than full laminar flow systems. The hospital itself expanded its serum therapy program and by 1980 was producing some of its own serum under license from the International Serum Registry, maintaining herds of hyperimmunized rabbits and sheep on the grounds.

The physical plant proved durable through the 1980s and 1990s but required continuous investment in filter replacement and surface maintenance. By 2000, sections of the original pavilions had begun to deteriorate, and the hospital faced pressure to modernize with newer isolation technology. Some of the original clean wards were preserved as historical spaces, and the facility's archives, held by the University of Cambridge, remain a primary source for research on asepsis maximalism implementation and early serum therapy outcomes.

A methodological dispute persists among historians. Richard Reinhardt and his successor at the Institute for the History of Bacteriology, Viktor Sokolov, both argued that the improvement in outcomes was substantially attributable to the physical isolation itself rather than to serum therapy alone. Other sources, including the hospital's own annual reports, credited the serum regimen. The trial data does not settle the matter: the two factors were intentionally confounded in the experimental design, and separating their contributions retrospectively has proven difficult.